Overall Survival with Inavolisib in <i>PIK3CA</i> -Mutated Advanced Breast Cancer

Komal L. Jhaveri

Breast and Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

Seock-Ah Im

Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, South Korea

Cristina Saura

Vall d’Hebron University Hospital, Barcelona

Sibylle Loibl

Johann Wolfgang Goethe Universität, Frankfurt am Main, Germany

Kevin Kalinsky

Winship Cancer Institute, Emory University, Atlanta

Peter Schmid

Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London

Sherene Loi

Eirini Thanopoulou

Roche, Welwyn Garden City, United Kingdom

Noopur Shankar

Genentech, San Francisco

Yanling Jin

Hoffmann–La Roche, Mississauga, ON, Canada

Thomas J. Stout

Genentech, San Francisco

Tiffany D. Clark

Genentech, San Francisco

Chunyan Song

Genentech, San Francisco

Dejan Juric

Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston

Nicholas C. Turner